Syncom Formulations (India) Limited: Company Profile

Background

Company Overview

Syncom Formulations (India) Limited, established in 1988, is a prominent player in the Indian pharmaceutical industry, specializing in the manufacturing and marketing of a diverse range of pharmaceutical formulations. The company operates through its state-of-the-art manufacturing facility located in Pithampur, Madhya Pradesh, India. This facility is WHO-GMP and ISO 9001:2015 certified, ensuring adherence to international quality standards.

Mission and Vision

Mission: Achieving customer delight by bringing a smile on every face.

Vision: To be a fully integrated and the most admired leading global healthcare provider.

Industry Significance

Syncom Formulations has established a significant presence in the pharmaceutical sector by offering a wide array of products that cater to various therapeutic segments. Its commitment to quality and customer satisfaction has enabled the company to expand its footprint both domestically and internationally.

Key Strategic Focus

Core Objectives

To manufacture and market a comprehensive range of pharmaceutical formulations.

To ensure high-quality standards in all products.

To expand global market reach by exporting products to multiple countries.

Areas of Specialization

Syncom Formulations specializes in the production of various pharmaceutical dosage forms, including:

Tablets

Capsules

Liquid Orals

Injectables (Liquid Vials and Ampoules)

Dry Powder Injections

Ophthalmic Preparations

Dry Syrups

Ointments, Creams, and Gels

Oral Rehydration Salts (ORS) and Jelly

Key Technologies Utilized

The company employs advanced manufacturing technologies to ensure product quality and efficiency. Specific details about proprietary technologies are not publicly disclosed.

Primary Markets Targeted

Syncom Formulations primarily targets:

Domestic markets within India

International markets, including approximately 25 countries worldwide

Financials and Funding

Funding History

Syncom Formulations is a publicly listed company on the Bombay Stock Exchange (BSE) under the ticker symbol 524470. The company has raised capital through public offerings and has a paid-up capital of ₹94.00 Crore.

Recent Financial Performance

In the financial year 2024, Syncom Formulations reported:

Total Revenue: ₹271.46 Crore, marking a 13.46% increase from the previous year.

Net Worth: ₹286.45 Crore, reflecting an 11.89% increase.

Profit: A 17.7% increase in profit compared to the previous year.

Intended Utilization of Capital

The company utilizes its capital to:

Expand manufacturing capacities

Enhance research and development efforts

Strengthen marketing and distribution networks

Pipeline Development

Key Pipeline Candidates

Specific details about pipeline candidates are not publicly disclosed.

Stages of Development

The company focuses on the development and manufacturing of a wide range of pharmaceutical formulations, with an emphasis on quality and compliance with international standards.

Target Conditions

Syncom Formulations' products address various therapeutic areas, including:

Infectious diseases

Cardiovascular conditions

Dermatological issues

Gastrointestinal disorders

Respiratory conditions

Pediatric care

Anticipated Milestones

The company aims to achieve:

Expansion of product offerings

Entry into new international markets

Enhancement of manufacturing capabilities

Technological Platform and Innovation

Proprietary Technologies

Specific proprietary technologies are not publicly disclosed.

Significant Scientific Methods

The company employs advanced manufacturing processes and quality control measures to ensure product efficacy and safety.

Leadership Team

Key Executives

Vijay Shankarlal Bankda: Managing Director

Kedarmal Shankarlal Bankda: Whole-Time Director

Ankit Kedarmal Bankda: Chief Financial Officer

Ritesh Kumar Lunkad: Director

Ankit Jain: Director

Ruchi Jindal: Director

Professional Backgrounds and Contributions

Vijay Shankarlal Bankda: With extensive experience in the pharmaceutical industry, he has been instrumental in the company's growth and expansion.

Kedarmal Shankarlal Bankda: Oversees daily operations and ensures compliance with industry standards.

Ankit Kedarmal Bankda: Manages financial strategies and operations, contributing to the company's financial stability.

Ritesh Kumar Lunkad: Provides strategic direction and governance.

Ankit Jain: Focuses on business development and market expansion.

Ruchi Jindal: Contributes to strategic planning and operational efficiency.

Competitor Profile

Market Insights and Dynamics

The Indian pharmaceutical industry is characterized by:

A large number of domestic and international players

A growing demand for generic medications

Increasing healthcare spending

Advancements in manufacturing technologies

Competitor Analysis

Syncom Formulations faces competition from various companies, including:

Lincoln Pharmaceuticals: Known for its diverse product portfolio and strong market presence.

M S Asterisk: Specializes in generic formulations with a focus on affordability.

M S Asterisk: Offers a range of pharmaceutical products catering to different therapeutic areas.

Strategic Collaborations and Partnerships

Syncom Formulations has established collaborations to enhance its market presence and product offerings. Specific details about these partnerships are not publicly disclosed.